Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05778708
Other study ID # UW22-583
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 13, 2023
Est. completion date October 2026

Study information

Verified date May 2023
Source The University of Hong Kong
Contact Chia-Chin Lin, PhD,FAAN,RN
Phone 39176633
Email cclin@hku.hk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this randomized controlled trial is to investigate the effects of Tai-Chi and aerobic exercise on the emotional symptom cluster, and the underlying mechanism of that cluster, in late-stage lung cancer patients. Participants will be randomized into one of three groups: 1) Tai-Chi group, 2) aerobic exercise group, or 3) self-management control group. Both the Tai-Chi and aerobic exercise groups will attend twice-weekly group classes for 16 weeks (32 total contact hours). The self-management control group will receive written information regarding the recommended level of physical activity.


Description:

Late-stage lung cancer patients (n = 318) meeting the inclusion criteria will be recruited and randomized into one of three groups: 1) Tai-Chi group, 2) aerobic exercise group, or 3) self-management control group. Both the Tai-Chi and aerobic exercise groups will attend twice-weekly group classes for 16 weeks (32 total contact hours). The self-management control group will receive written information regarding the recommended level of physical activity. To evaluate the effectiveness of Tai-Chi and aerobic exercise in alleviating the emotional symptom cluster (primary outcome) and individual symptoms (sleep disturbance, anxiety, depression, fatigue), outcome measures will be conducted at baseline, 8 weeks (mid-point assessment), 16 weeks (post-intervention), and 28 weeks (12-weeks post-intervention). A linear mixed-effects model will be used to study the between-group differences in outcomes. In addition, emotion regulation, mindfulness, and cardiorespiratory fitness will be evaluated at each data collection point, and structural equation modeling will be used for subsequent mediation analysis to determine their mediating role in outcome changes. Qualitative interviews will be conducted to understand patients' experience and evaluation of the interventions.


Recruitment information / eligibility

Status Recruiting
Enrollment 318
Est. completion date October 2026
Est. primary completion date February 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - diagnosed with stage IIIB or IV non-small cell lung cancer confirmed by pathology, with no other cancer diagnosis within the previous year; - a current Eastern Cooperative Oncology Group Performance Status of 0-2; - experience of sleep disturbance, anxiety, depression, and fatigue in the past week (rating of 1 or more on a 0-10 numeric rating scale [NRS] for each symptom); - able to communicate in Cantonese, Mandarin, or English; - conscious and alert Exclusion Criteria: - suffering from a condition that hinders exercise performance (e.g., active neurological disorder, recent heart attack); - currently participating in any other exercise or mind-body classes; or 3) performing regular exercises, defined as at least 150 minutes of moderate-intensity exercise weekly

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Tai-Chi intervention
The standardized 16-form Yang-style Tai-Chi exercise set will be adopted. Group classes will take place in a community center twice a week for 16 weeks, with each class lasting approximately 60 minutes. Classes will be taught by an experienced Tai-Chi master. Patients will be instructed to practice the Tai-Chi exercises at home at least 3 times a week (30 min each time for a total of 90 min). Patients will be provided with a daily exercise log to record their exercise type, frequency, and intensity.
Aerobic exercise intervention
The aerobic exercise class will be designed to cover both aerobic and resistance exercises. Group classes will take place in an exercise center twice a week for 16 weeks, with each class lasting approximately 60 minutes. Each class will be led by a certified exercise specialist. Patients will be provided with a daily exercise log to record their exercise type, frequency, and intensity.

Locations

Country Name City State
Hong Kong Queen Mary Hospital Hong Kong

Sponsors (2)

Lead Sponsor Collaborator
The University of Hong Kong Queen Mary Hospital, Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline Emotional symptom cluster at 8 weeks NRSs for assessing each symptom of sleep disturbance, anxiety, depression, and fatigue over the past 7 days will be used to measure emotional symptom cluster severity. Higher score indicates more severe symptoms. 8 weeks
Primary Change from Baseline Emotional symptom cluster at 16 weeks NRSs for assessing each symptom of sleep disturbance, anxiety, depression, and fatigue over the past 7 days will be used to measure emotional symptom cluster severity. Higher score indicates more severe symptoms. 16 weeks
Primary Change from Baseline Emotional symptom cluster at 28 weeks NRSs for assessing each symptom of sleep disturbance, anxiety, depression, and fatigue over the past 7 days will be used to measure emotional symptom cluster severity. Higher score indicates more severe symptoms. 28 weeks
Secondary Change from Baseline Sleep disturbance at 8 weeks Measured by the Pittsburg Sleep Quality Index. The total score ranges from 0-21, with higher scores denoting poorer sleep. 8 weeks
Secondary Change from Baseline Sleep disturbance at 16 weeks Measured by the Pittsburg Sleep Quality Index. The total score ranges from 0-21, with higher scores denoting poorer sleep. 16 weeks
Secondary Change from Baseline Sleep disturbance at 28 weeks Measured by the Pittsburg Sleep Quality Index. The total score ranges from 0-21, with higher scores denoting poorer sleep. 28 weeks
Secondary Change from Baseline Fatigue at 8 weeks Measured by the Brief Fatigue Inventory. Higher score denotes worse fatigue level. 8 weeks
Secondary Change from Baseline Fatigue at 16 weeks Measured by the Brief Fatigue Inventory. Higher score denotes worse fatigue level. 16 weeks
Secondary Change from Baseline Fatigue at 28 weeks Measured by the Brief Fatigue Inventory. Higher score denotes worse fatigue level. 28 weeks
Secondary Change from Baseline Anxiety and depression at 8 weeks Measured by the Hospital Anxiety and Depression Scale. Higher score denotes higher level of anxiety and depression. 8 weeks
Secondary Change from Baseline Anxiety and depression at 16 weeks Measured by the Hospital Anxiety and Depression Scale. Higher score denotes higher level of anxiety and depression. 16 weeks
Secondary Change from Baseline Anxiety and depression at 28 weeks Measured by the Hospital Anxiety and Depression Scale. Higher score denotes higher level of anxiety and depression. 28 weeks
Secondary Change from Baseline Emotion regulation at 8 weeks Measured by the Emotion Regulation Questionnaire. Higher scores indicating greater usage of that strategy. 8 weeks
Secondary Change from Baseline Emotion regulation at 16 weeks Measured by the Emotion Regulation Questionnaire. Higher scores indicating greater usage of that strategy. 16 weeks
Secondary Change from Baseline Emotion regulation at 28 weeks Measured by the Emotion Regulation Questionnaire. Higher scores indicating greater usage of that strategy. 28 weeks
Secondary Change from Baseline Mindfulness at 8 weeks Measured by the Five Facet Mindfulness Questionnaire-Short Form. Higher score denotes higher mindfulness experience. 8 weeks
Secondary Change from Baseline Mindfulness at 16 weeks Measured by the Five Facet Mindfulness Questionnaire-Short Form. Higher score denotes higher mindfulness experience. 16 weeks
Secondary Change from Baseline Mindfulness at 28 weeks Measured by the Five Facet Mindfulness Questionnaire-Short Form. Higher score denotes higher mindfulness experience. 28 weeks
Secondary Change from Baseline Cardiorespiratory fitness at 8 weeks Measured by the six-minute walk test. The distance walked at the end of 6 minutes will be measured in meters. 8 weeks
Secondary Change from Baseline Cardiorespiratory fitness at 16 weeks Measured by the six-minute walk test. The distance walked at the end of 6 minutes will be measured in meters. 16 weeks
Secondary Change from Baseline Cardiorespiratory fitness at 28 weeks Measured by the six-minute walk test. The distance walked at the end of 6 minutes will be measured in meters. 28 weeks
Secondary Change from Baseline agility at 8 weeks Measured by the timed up-and-go test; unit: second. 8 weeks
Secondary Change from Baseline agility at 16 weeks Measured by the timed up-and-go test; unit: second. 16 weeks
Secondary Change from Baseline agility at 28 weeks Measured by the timed up-and-go test; unit: second. 28 weeks
Secondary Change from Baseline strength at 8 weeks Measured by the sit-to-stand test; unit: number of times. 8 weeks
Secondary Change from Baseline strength at 16 weeks Measured by the sit-to-stand test; unit: number of times. 16 weeks
Secondary Change from Baseline strength at 28 weeks Measured by the sit-to-stand test; unit: number of times. 28 weeks
Secondary Change from Baseline balance at 8 weeks Measured by the single-leg standing test; ; unit: second. 8 weeks
Secondary Change from Baseline balance at 16 weeks Measured by the single-leg standing test; ; unit: second. 16 weeks
Secondary Change from Baseline balance at 28 weeks Measured by the single-leg standing test; ; unit: second. 28 weeks
See also
  Status Clinical Trial Phase
Terminated NCT04396535 - Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer Phase 2
Withdrawn NCT04186988 - [18F]-AraG for the Detection of T-Cell Activation in Advanced Non-small Cell Lung Cancer Patients Undergoing PD-1/PD-L1-Directed Therapy Early Phase 1
Active, not recruiting NCT04514484 - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Phase 1
Recruiting NCT06096844 - Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial Phase 3
Recruiting NCT06249282 - Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer Phase 1
Recruiting NCT05166616 - Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer Phase 1
Active, not recruiting NCT02983578 - Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer Phase 2
Recruiting NCT03831932 - Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT05096663 - Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) Phase 2/Phase 3
Not yet recruiting NCT05498389 - EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer Phase 1/Phase 2
Recruiting NCT05967533 - The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors Phase 1
Recruiting NCT05334329 - Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors Phase 1
Recruiting NCT04856176 - A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy Phase 2
Recruiting NCT05198154 - ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC
Recruiting NCT04762199 - MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer Phase 1
Active, not recruiting NCT04491942 - Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer Phase 1
Active, not recruiting NCT05407038 - Remote Monitoring With Health-Coaching for Lifestyle Changes in Patients With Lung Cancer Related Fatigue N/A
Recruiting NCT03191149 - Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Phase 2
Recruiting NCT05339022 - Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial N/A
Recruiting NCT04902040 - Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies Phase 1/Phase 2